MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts
As part of its strategic prioritization, Moderna aims to cut its R&D expenses by 20% over the next four years. It decides to end five pipeline programs to save costs.
| Ticker |
Sentiment |
Impact |
|
MRNA
|
Neutral
|
61 %
|
|
BX
|
Neutral
|
4 %
|
|
PFE
|
Neutral
|
4 %
|
|
SNY
|
Neutral
|
8 %
|
